viralytics in the media, page-8

An additional four recruitment sites anticipated for this month, as noted in the latest VLA newsletter, will double the number of trial sites. The criteria for selection of suitable patients are quite stringent, which is another reason for what may seem to us lay people to be a rather slow process. I would expect that doubling the sites implies a substantial increase in the number of clinicians aware of CAVATAK's potential, and potentially a doubling in the rate of patient recruitment. But I do not know the distribution of patients by number or condition across the eight sites, so my expectation must remain as that, sheer optimism! But I would expect a noticeable increase in the rate of recruitment.

As others have noted, the critical information is the proportion of trial patients proceeding to a second round of injections in an extension study; they can do so only if their tumours have stabilised or reduced. Good news indeed for the patients concerned, and if the proportion is statistically significant, good news for VLA.